Sonia Gera

Dr. Sonia Gera

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2020 in Advanced Functional Materials
Verified
Journal Article
Open access
PDF file
JWJitendra Wankar
Jitendra Wankar
NKNiranjan Kotla
Niranjan Kotla
SGSonia Gera
Sonia Gera
SRSwetha Rasala
Swetha Rasala
Abhay PanditAbhay Pandit
Abhay Pandit
YRYury Rochev
Yury Rochev
This Review is an overview of the unique characteristics of cyclodextrin in forming an inclusion complex via host–guest noncovalent interactions. The modification of cyclodextrin advances its application as a pharmaceutical solubilizer, fabrication of functional molecular machines such as polyrotaxane, polypseudorotaxane, and polycatenanes and grafting of cyclodextrin with different linear, branched chain polymers. The different stimuli‐based supramolecular assemblies involving cyclodextrin as a key mediator with linked triggering responses on payload release is highlighted. In addition, the applications of cyclodextrin in diagnostic imaging and medical devices is briefly demonstrated. Cyclodextrin is a relatively low cost, biocompatible, biodegradable, and highly explored material with low toxicity for drug formulation, drug delivery, and wide varieties of other biomedical applications such as those in medical devices fabrication, biosensor, tissue engineering, and bio‐imaging. The toxicological profile of cyclodextrin is well established and safe for human consumption in food and medicine.

22 May 2017 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
SGSonia Gera
Sonia Gera
STSreekanth Talluri
Sreekanth Talluri
NRNagarjun Rangaraj
Nagarjun Rangaraj
DSDr.Sunitha Sampathi
Dr.Sunitha Sampathi

13 May 2020 in Pharmaceutical Development and Technology
Verified
Journal Article
Closed access
SGSonia Gera
Sonia Gera
VPVenkatesh Pooladanda
Venkatesh Pooladanda
CGChandraiah Godugu
Chandraiah Godugu
VCVeerabhadra Swamy Challa
Veerabhadra Swamy Challa
JWJitendra Wankar
Jitendra Wankar
DSDr.Sunitha Sampathi
Dr.Sunitha Sampathi
Clinical significance of Rutin (RUT) is limited by poor dissolution rate and low oral bioavailability. The study was designed to improve the physicochemical and therapeutic potential of the drug by formulating nanosuspension (NS) for osteoporosis. Rutin nanosuspension (RUT-NS) was prepared after screening a range of stabilizers and their combinations at a different concentration by antisolvent precipitation technique. Effect of precipitation on crystallinity (differential scanning calorimetry DSC, X-ray diffraction studies XRD), morphology (scanning electron microscopy, SEM) and chemical interaction (attenuated total reflectance fourier-transform infrared spectroscopy ATR-FTIR) were studied through biophysical techniques. An optimized nanosuspension exhibited a minimum particle size of 122.85 ± 5.02 nm with higher dissolution of RUT-NS (87. 63 ± 2.29%) as compared to pure drug (39.77 ± 2.8 6%). The enhanced intestine absorption and apparent permeability were achieved due to the improved particle size, surface area and dissolution. RUT-NS displayed greater (3 folds) AUC0–24 h than pure drug. In vitro assays with RUT-NS depicted an increased cell proliferation, antioxidant (ROS) activity and osteocalcin production in MG-63 osteoblast cells. The augmented biochemical in vivo biomarkers and bone quality proved the protective effect of RUT-NS. The results supported RUT-NS as a potential therapy for maintaining bone health.

11 July 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SGSonia Gera
Sonia Gera
DSDr.Sunitha Sampathi
Dr.Sunitha Sampathi
SMSravya Maddukuri
Sravya Maddukuri
SDSujatha Dodoala
Sujatha Dodoala
DSDr.Sunitha Sampathi
Dr.Sunitha Sampathi
Sathish DyawanapellySathish Dyawanapelly
Sathish Dyawanapelly
Naringenin (NRG) is a flavonoid and has been reported as an anti-osteoporotic agent. However, poor bioavailability may limit the anti-osteoporotic potential of the drug. The purpose of the study was to compare the anti-osteoporotic activity of naringenin nanosuspension (NRG-NS) with the NRG and standard therapeutic drug, raloxifene hydrochloride (RLX). Here, NRG-NS showed anti-osteoporotic activity in MG-63 cells by upregulating the osteocalcin levels. The in vivo anti-osteoporotic activity of NRG-NS was further investigated in an osteoporotic rat model to mimic the post-menopausal condition. The animals were randomized and separated into six groups. The animals were treated with RLX (p.o., 5.4 mg/kg), NRG (p.o., 20 mg/kg), NRG-NS (p.o., 20 mg/kg), and blank-NS for 60 days after completion of a 30-day post-surgery period and compared with control and ovariectomized (OVX) groups. After the treatment, body and uterine weights, biochemical estimation in serum (calcium, phosphorus, acid phosphatase, alkaline phosphatase, osteocalcin), bone parameters (length, diameter, dry weight, density, ash weight, bone mineral content) and bone microarchitecture by histopathology were determined. The results showed the protective effects of NRG-NS on osteoblast-like MG-63 cells. The biochemical estimations confirmed the normalization of parameters viz., alkaline phosphatase, calcium concentrations, and bone density with a decrease in levels of acid phosphatase and inorganic phosphorus with NRG-NS as compared to plain NRG. The results indicated that the oral administration of NRG-NS could be a potential therapeutic formulation for the treatment of osteoporosis.

16 October 2017 in Current Drug Delivery
Verified
Journal Article
Closed access
PDF file
SGSonia Gera
Sonia Gera
DSDr.Sunitha Sampathi
Dr.Sunitha Sampathi
SDSujatha Dodoala
Sujatha Dodoala
Background: Osteoporosis is a disease characterized by progressive bone loss due to aging and menopause in women leading to bone fragility with increased susceptibility towards fractures. The silent disease weakens the bone by altering its microstructure and mass. Therapy is based on either promoting strength (via osteoblast action) or preventing disease (via osteoclast action). Current therapy with different drugs belonging to antiresorptive, anabolic and hormonal classification suffers from poor pharmacokinetic and pharmacodynamic profile. Objectives: Nanoparticles provide breakthrough as an alternative therapeutic carrier and biomedical imaging tool in bone diseases. The current review highlights bone physiology and pathology along with potential applications of nanoparticles in osteoporosis through use of organic and inorganic particles for drug delivery, biomedical imaging as well as bone tissue regeneration therapy. Results: Inorganic nanoparticles of gold, cerium, platinum and silica have effects on osteoblastic and osteoclastic lineage. Labelling and tracking of bone cells by quantum dots and gold nanoparticles are advanced and non-invasive techniques. Incorporation of nanoparticles into the scaffolds is a more recent technique for improving mechanical strength as well as regeneration during bone grafting. Conclusions: Promising results by in vitro and in vivo studies depicts effects of nanoparticles on biochemical markers and biomechanical parameters during osteoporosis suggesting the bright future of nanoparticles in bone applications. Any therapy which improves the drug profile and delivery to bone tissue will be promising approach. Superparamagnetic, gold, mesoporous silica nanoparticles and quantum dots provide golden opportunities for biomedical imaging by replacing the traditional invasive radionuclide techniques.